Akeso Inc
HKEX:9926

Watchlist Manager
Akeso Inc Logo
Akeso Inc
HKEX:9926
Watchlist
Price: 60 HKD -1.4% Market Closed
Market Cap: 53.9B HKD
Have any thoughts about
Akeso Inc?
Write Note

Akeso Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Akeso Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Akeso Inc
HKEX:9926
Accrued Liabilities
ÂĄ134.4m
CAGR 3-Years
57%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accrued Liabilities
ÂĄ2.6B
CAGR 3-Years
49%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Accrued Liabilities
ÂĄ1.1B
CAGR 3-Years
8%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accrued Liabilities
ÂĄ268.5m
CAGR 3-Years
37%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accrued Liabilities
ÂĄ325.2m
CAGR 3-Years
-8%
CAGR 5-Years
85%
CAGR 10-Years
60%
Imeik Technology Development Co Ltd
SZSE:300896
Accrued Liabilities
ÂĄ116.1m
CAGR 3-Years
52%
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Akeso Inc
Glance View

Market Cap
52B HKD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

Intrinsic Value
59.24 HKD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Akeso Inc's Accrued Liabilities?
Accrued Liabilities
134.4m CNY

Based on the financial report for Dec 31, 2023, Akeso Inc's Accrued Liabilities amounts to 134.4m CNY.

What is Akeso Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
81%

Over the last year, the Accrued Liabilities growth was 0%. The average annual Accrued Liabilities growth rates for Akeso Inc have been 57% over the past three years , 81% over the past five years .

Back to Top